The folate receptor is a highly selective tumor marker overexpressed in greater than 90% of
ovarian carcinomas. Two general strategies have been developed for the targeted delivery …

Although hydrophilic small molecule drugs are widely used in the clinic, their rapid
clearance, suboptimal biodistribution, low intracellular absorption and toxicity can limit their …

Cell-penetrating peptides (CPPs) are short peptides (fewer than 30 amino acids) that have
been predominantly used in basic and preclinical research during the last 30 years. Since …

Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib
(PLX4032) have shown response rates of more than 50% in patients with metastatic …

Background Approximately 50% of melanomas harbor activating (V600) mutations in the
serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib …

Background Individuals with cancer, particularly those who are receiving systemic
anticancer treatments, have been postulated to be at increased risk of mortality from COVID …

Background The identification of somatic mutations in the gene encoding the serine–
threonine protein kinase B-RAF (BRAF) in the majority of melanomas offers an opportunity to …

B-RAF is the most frequently mutated protein kinase in human cancers. The finding that
oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that …

Background Patients with cancer are purported to have poor COVID-19 outcomes. However,
cancer is a heterogeneous group of diseases, encompassing a spectrum of tumour …

Rare circulating tumor cells (CTCs) present in the bloodstream of patients with cancer
provide a potentially accessible source for detection, characterization, and monitoring of …